Improvement of endothelial function by pitavastatin: a meta-analysis

ABSTRACT Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.

[1]  J. Car,et al.  Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. , 2016, Atherosclerosis. Supplements.

[2]  P. Poredos,et al.  Testing endothelial function and its clinical relevance. , 2013, Journal of atherosclerosis and thrombosis.

[3]  Ž. Reiner.  Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  M. Banach,et al.  HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. , 2017, Progress in lipid research.

[5]  M. Ishihara,et al.  Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia , 2013, Heart Asia.

[6]  Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[7]  E. Mannarino,et al.  Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function , 2009, Journal of cardiovascular pharmacology and therapeutics.

[8]  Elina Taneva,et al.  Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. , 2006, The American journal of cardiology.

[9]  H. Takagi,et al.  Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials. , 2012, International journal of cardiology.

[10]  Ž. Reiner.  Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.

[11]  M. Banach,et al.  Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. , 2015, Atherosclerosis.

[12]  Ž. Reiner,et al.  Adverse effects of statins - myths and reality. , 2015, Current pharmaceutical design.

[13]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Funahashi,et al.  Importance of assessing the effect of statins on the function of high- density lipoproteins on coronary plaque. , 2012, Cardiovascular & hematological disorders drug targets.

[15]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[16]  N. Suksomboon,et al.  Meta‐analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia , 2012, Journal of clinical pharmacy and therapeutics.

[17]  Jing Zhao,et al.  Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia , 2015, Journal of Zhejiang University-SCIENCE B.

[18]  C. Mantzoros,et al.  New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! , 2015, Metabolism: clinical and experimental.

[19]  A. Kashiwagi,et al.  Pitavastatin Restores Vascular Dysfunction in Insulin-Resistant State by Inhibiting NAD(P)H Oxidase Activity and Uncoupled Endothelial Nitric Oxide Synthase-Dependent Superoxide Production , 2007, Journal of cardiovascular pharmacology.

[20]  M. Endo,et al.  Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects , 2011, Heart and Vessels.

[21]  M. Pirro,et al.  Review: Hypercholesterolemia-associated endothelial progenitor cell dysfunction , 2008, Therapeutic advances in cardiovascular disease.

[22]  Liheng Qiu,et al.  Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials , 2014, Clinical Drug Investigation.

[23]  M. Bots,et al.  Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. , 2005, European heart journal.

[24]  M. Banach,et al.  Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. , 2013, Current pharmaceutical design.

[25]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[26]  U. Förstermann,et al.  Vascular oxidative stress, nitric oxide and atherosclerosis. , 2014, Atherosclerosis.

[27]  S. Ramkumar,et al.  Statin Therapy: Review of Safety and Potential Side Effects. , 2016, Acta Cardiologica Sinica.

[28]  K. Koh,et al.  Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. , 2016, International journal of cardiology.

[29]  F. Faita,et al.  Non-invasive diagnostic tools for investigating endothelial dysfunction. , 2008, Current pharmaceutical design.

[30]  W. Kim,et al.  Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. , 2007, Clinical therapeutics.

[31]  K. Parhofer,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects* , 2022 .

[32]  Maciej Banach,et al.  Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies , 2015, BMC Medicine.

[33]  T. Rabelink,et al.  Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. , 2001, Cardiovascular research.

[34]  A. Sahebkar,et al.  Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Pharmacological research.

[35]  C. Lang,et al.  Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus. , 2008, Cardiovascular therapeutics.

[36]  M. Azarpazhooh,et al.  Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial , 2011, Lipids.

[37]  J. Car,et al.  Familial hypercholesterolaemia: a global call to arms , 2015 .

[38]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[39]  H. Utsumi,et al.  Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. , 2005, Free radical biology & medicine.

[40]  L. Ose.  Pitavastatin: finding its place in therapy , 2011, Therapeutic advances in chronic disease.

[41]  A. Papavassiliou,et al.  Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. , 2013, Atherosclerosis.

[42]  A. Sahebkar.  Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. , 2013, Nutrition reviews.

[43]  A. Sahebkar,et al.  Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. , 2015, Pharmacological research.

[44]  A. Sahebkar,et al.  A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations , 2015, Scientific Reports.

[45]  A. Sahebkar,et al.  Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.

[46]  Y. Ogura,et al.  Pitavastatin Attenuates Leukocyte-Endothelial Interactions Induced by Ischemia-Reperfusion Injury in the Rat Retina , 2009, Current eye research.

[47]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[48]  B. Zhang,et al.  Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[49]  M. Urashima,et al.  New evidence on pitavastatin: efficacy and safety in clinical studies , 2010, Expert opinion on pharmacotherapy.

[50]  M. Bertolami,et al.  One-Month Therapy with Simvastatin Restores Endothelial Function in Hypercholesterolemic Children and Adolescents , 2007, Pediatric Cardiology.

[51]  C. Stefanadis,et al.  Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta , 2011, Heart.

[52]  Yongbin Lu,et al.  Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. , 2016, Atherosclerosis.

[53]  Jing Zhao,et al.  The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia , 2011, Expert opinion on pharmacotherapy.

[54]  A. Sahebkar,et al.  Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. , 2015, Progress in lipid research.

[55]  L. Jensen,et al.  Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. , 2012, International journal of cardiology.

[56]  S. Duggan.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. , 2012, Drugs.

[57]  K. Yokote,et al.  Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). , 2009, Journal of atherosclerosis and thrombosis.

[58]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[59]  A. Sahebkar,et al.  A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations , 2015, Scientific Reports.

[60]  A. Sahebkar.  Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. , 2013, DNA and cell biology.

[61]  J. Gumprecht,et al.  Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia , 2011, Diabetes, obesity & metabolism.

[62]  Toshio Hayashi,et al.  A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. , 2010, International journal of cardiology.

[63]  Y. Fukuda,et al.  Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. , 2008, International journal of cardiology.

[64]  Ž. Reiner,et al.  Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality , 2012, Current Cardiology Reports.